management team

Dr. Clarke was promoted to Chief Executive Officer of Pulmatrix in 2012 after serving as the Chief Scientific Officer. Joining Pulmatrix in 2004 as the first PhD level scientist, his role evolved to oversight of Research and Development efforts at Pulmatrix focused on developing the Pulmatrix technologies for treatment of respiratory disease. He has helped raise greater than $60 million in venture capital funding for the company as well as secured more than $10 million in non-dilutive funding to support Pulmatrix R&D programs. Previous to Pulmatrix, he was an Associate Director of Life Sciences at Alkermes, Inc. focused mainly on developing inhaled therapeutic products with the AIR® technology platform. Dr. Clarke holds a B.Sc. in Biomedical Engineering from Boston University, has his Ph.D. in Physiology from Johns Hopkins University, and completed his post-doctoral training in Respiratory Biology at Brigham and Women’s Hospital and Harvard University. Dr. Clarke has over a dozen years industry and over 20 years total experience focused on pulmonary drug delivery and the role of inhaled particles in respiratory biology and medicine leading to co-authorship of over 80 chapters, papers, and abstracts.

Dr. Hava was promoted to CSO in November of 2012 after previously acting as Vice President of Research and Therapeutic Strategy at Pulmatrix.  As CSO, Dr. Hava leads the Research and Development organization in the development of iSPERSE products across all stages of preclinical and clinical development.  In addition, Dr. Hava directs and manages the company’s therapeutic strategy to identify and prioritize drug targets and drugs that are enabled by the iSPERSE dry powder delivery platform.  Dr. Hava joined Pulmatrix in 2006 as one of the first Senior Scientists and has been involved in the early stage research and development programs that identified and characterized several of the key aspects of the Pulmatrix technology.  Dr. Hava earned his PhD. in Molecular Biology and Microbiology at Tufts University and completed his post-doctoral training studying immunology and host-pathogen interactions at Harvard Medical School.  Dr. Hava has co-authored over 20 papers and abstracts focused on pulmonary infectious disease, immunology and chronic lung diseases.

Molly Rosano joined Pulmatrix in 2009 and has more than 20 years of experience in the pharmaceutical/biotechnology industry. Prior to joining Pulmatrix, Ms. Rosano was the Director of Clinical Affairs at Pervasis Therapeutics, where she served in a leadership role in the development and execution of clinical programs. Her experience spans all phases of clinical development and post-marketing research, and she has conducted trials in North America, Europe and Asia. In addition, Ms. Rosano has experience in the development of inhaled therapeutics for asthma, chronic obstructive pulmonary disease and cystic fibrosis. She previously held positions in clinical research, market research, and sales at Sepracor (now Sunovion), MORPACE Pharma Group, Astra USA, Boots Pharmaceuticals and Abbott Laboratories. Ms. Rosano has been a panel speaker for the Drug Information Association, Massachusetts Biotechnology Council and various other organizations regarding the execution of large multi-center clinical trials and use of new technology in clinical trials. Ms. Rosano holds a B.S. in Biology from Siena College and an M.B.A. from Regis University.

Jaisim Shah has over 25 years of global biopharma experience including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. Prior to Pulmatrix, he was the Chief Business Officer of Elevation Pharmaceuticals, where he led a successful sale of Elevation to Sunovion, a division of Dainippon Sumitomo Pharma in September 2012. Prior to Elevation, he was president of Zelos Therapeutics, where he focused on financing and business development. Prior to Zelos, he was the Chief Business Officer at CytRx, a biopharmaceutical company. Prior to CytRx, Jaisim was Chief Business Officer at Facet Biotech and PDL BioPharma where he led commercial operations and completed numerous licensing/partnering and strategic transactions with pharmaceutical and biotech companies. Prior to PDL he was at Bristol-Myers Squibb, as Vice President of Global and US Marketing where he received the “Presidents Award” for completing one of the most significant collaborations in the company’s history. Prior to working with Bristol-Myers Squibb, Mr. Shah was at F. Hoffman-La Roche in US & In Basel as Global business leader for corporate alliances with Genentech and Idec. Jaisim holds an MA in Economics from the University of Akron and an MBA from Oklahoma University.

Dr. Sung has spent over a decade developing novel particle engineering and formulation technologies to advance respiratory dry powder drug delivery. Dr. Sung joined Pulmatrix in 2008, leading the formulation, process, particle engineering and analytical chemistry development functions. Prior to her graduate studies, Dr. Sung was an early employee at Advanced Inhalation Research (AIR^®) Inc. and later Alkermes, Inc. after the acquisition of AIR, where she advanced formulation development of the pulmonary drug delivery platform technology across small molecule and macromolecule therapies. Dr. Sung has numerous scientific publications and patents/applications in drug delivery, primarily focused on particle formulations for inhaled therapeutics. Dr. Sung has a S.B. in Chemical Engineering from Massachusetts Institute of Technology and holds a Ph.D. and M.S. in Engineering Sciences with a focus on Biomedical Engineering from Harvard University.